Olema Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company based in San Francisco that develops targeted therapies for women's cancers, especially breast cancer. Its lead drug candidate, palazestrant (OP-1250), is an oral pill designed to block the estrogen receptor that fuels many breast tumors, offering patients a daily-at-home option instead of an injection. Founded in 2016, the company went public in 2020 to fund its clinical trials.
Bought 300.0K
Bought 100.0K · Sold 2.40M
Bought 3.58M
Bought 425.0K
Bought 2.50M · Sold 1.88M
Granted 143.5K
Granted 45.0K · Sold 441.3K
Granted 318.5K · Sold 241.4K
Granted 35.9K
Granted 376.6K · Bought 20.0K · Sold 176.7K
Granted 548.7K · Bought 30.0K · Sold 157.7K
Granted 293.2K · Sold 311.9K
Granted 83.9K
Granted 11.7K
Granted 132.7K · Sold 127.4K
Granted 40.0K · Sold 40.0K
Granted 264.8K · Sold 264.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Fund IV, L.P. +4 co-filers10% owner · 2 transactions | — | 7.50Mas of Jan 2025 | — | 300.0K | — |
| Asefaw Senai +3 co-filers10% owner · 3 transactions | — | 5.50Mas of Aug 2024 | — | 100.0K | 2.40M |
| Biotechnology Value Fund II LP +9 co-filersDirector, See Explanation of Responses · 28 transactions | — | 4.76M | — | 3.58M | — |
| Chen Bihua +4 co-filersDirector, 10% owner, Former 10% Owner, 10% owner · 2 transactions | — | 2.85Mas of Nov 2020 | — | 425.0K | — |
| Graham G. WalmsleyDirector · 11 transactions | — | 1.80Mas of May 2025 | — | 2.50M | 1.88M |
| Kushner Peter J.Chief Scientific Officer · 3 transactions | — | 1.30Mas of Nov 2020 | 143.5K | — | — |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P.10% owner · 2 transactions | — | 1.27Mas of Nov 2020 | — | — | — |
| Harmon CyrusDirector · 52 transactions | — | 961.8K | 45.0K | — | 441.3K |
| Myles David C.CH. DISCOV. & NON-CLIN DEV OFF · 28 transactions | — | 700.4K | 318.5K | — | 241.4K |
| Rappaport AndrewDirector · 6 transactions | — | 386.0K | 35.9K | — | — |
| McCormick FrankDirector · 2 transactions | — | 275.4Kas of Nov 2020 | — | — | — |
| Bohen SeanPresident and CEO, Director · 22 transactions | — | 237.7K | 376.6K | 20.0K | 176.7K |
| Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF. · 18 transactions | — | 139.7K | 548.7K | 30.0K | 157.7K |
| Zojwalla NaseemChief Medical Officer · 22 transactions | — | 104.0K | 293.2K | — | 311.9K |
| Butitta Cynthia MDirector · 1 transaction | — | 83.9Kas of Nov 2020 | 83.9K | — | — |
| Austin Sasha LuVP of Finance and Controller · 1 transaction | — | 4.5K | 11.7K | — | — |
| Horn KinneyCHIEF BUSINESS OFFICER · 29 transactions | — | 2.5Kas of Mar 2022 | 132.7K | — | 127.4K |
| Mitchell ShawnteCHIEF LEGAL OFFICER · 5 transactions | — | 233 | 40.0K | — | 40.0K |
| Clark Ian TDirector · 7 transactions | — | 0 | 264.8K | — | 264.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +919.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.